Abstract | OBJECTIVE: METHODS: RESULTS: CONCLUSIONS: These findings indicate that tyrosine kinase activity is a common characteristic of ALCLs and necessary for ALCL cell survival. These findings further suggest that therapies targeting tyrosine kinases, including p80, may have clinical utility.
|
Authors | M Ergin, M F Denning, K F Izban, H M Amin, R L Martinez, S Saeed, S Alkan |
Journal | Experimental hematology
(Exp Hematol)
Vol. 29
Issue 9
Pg. 1082-90
(Sep 2001)
ISSN: 0301-472X [Print] Netherlands |
PMID | 11532349
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Benzoquinones
- Enzyme Inhibitors
- Lactams, Macrocyclic
- Oncogene Proteins, Fusion
- Piperazines
- Pyrimidines
- Quinones
- Rifabutin
- herbimycin
- Imatinib Mesylate
- p80(NPM-ALK) protein
- ALK protein, human
- Anaplastic Lymphoma Kinase
- Protein-Tyrosine Kinases
- Receptor Protein-Tyrosine Kinases
- Caspases
|
Topics |
- Anaplastic Lymphoma Kinase
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects)
- Benzamides
- Benzoquinones
- Caspases
(pharmacology)
- Chromosomes, Human, Pair 2
- Chromosomes, Human, Pair 5
- Enzyme Inhibitors
(pharmacology)
- Hodgkin Disease
(pathology)
- Humans
- Imatinib Mesylate
- Immunohistochemistry
- Lactams, Macrocyclic
- Lymphoma, Large B-Cell, Diffuse
(pathology)
- Oncogene Proteins, Fusion
(genetics, metabolism)
- Phosphorylation
- Piperazines
(pharmacology)
- Protein-Tyrosine Kinases
(antagonists & inhibitors, genetics, metabolism)
- Pyrimidines
(pharmacology)
- Quinones
(pharmacology)
- Receptor Protein-Tyrosine Kinases
- Rifabutin
(analogs & derivatives)
- Translocation, Genetic
- Tumor Cells, Cultured
(drug effects)
|